Pfizer Wins Priority Review Voucher for Paxlovid
Federal Register notice: FDA is issuing a priority review voucher to Pfizer after determining that its Paxlovid (nirmatrelvir co-packaged with ritonavir) tablets meet the criteria for a material threat medical countermeasure product application. The drug was approved 5/2023 for treating mild-to-moderate Covid-19. To view the notice, click here.